PAMELA MALIAVSKY: Open Payments
NPI 1578846838 · VERONA, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,313 in 80 payments from 15 companies in 2025. Trend: 2023 $880 · 2024 $1,078 · 2025 $1,313
Food & beverage: $1,313
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 31 | $486 |
| Corcept Therapeutics | 11 | $171 |
| AstraZeneca Pharmaceuticals LP | 8 | $136 |
| ABBVIE INC. | 7 | $116 |
| Amgen Inc. | 6 | $101 |
| Novartis Pharmaceuticals Corporation | 4 | $71 |
| Lilly USA, LLC | 3 | $55 |
| Lundbeck LLC | 2 | $36 |
| GlaxoSmithKline, LLC. | 2 | $33 |
| Exact Sciences Corporation | 1 | $26 |
Products named: Korlym, Ozempic, Wegovy, LEQVIO, FARXIGA, Rybelsus, QULIPTA, VRAYLAR.
Industry payments across NJ — which companies pay providers there.
